Risk of second primary malignancies after nasopharyngeal carcinoma: A population-based cohort study in Taiwan

Head & Neck ◽  
2013 ◽  
Vol 36 (2) ◽  
pp. 209-214 ◽  
Author(s):  
Charlene Lin ◽  
Shih-Wei Lin ◽  
Shih-Feng Weng ◽  
Yung-Song Lin
Keyword(s):  
Cohort Study ◽  
Nasopharyngeal Carcinoma ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancies

scholarly journals Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Catherine W. Saltus ◽  
Zdravko P. Vassilev ◽  
Jihong Zong ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Cohort Study ◽  
Incidence Rate ◽  
Retrospective Cohort ◽  
Population Based ◽  
Second Primary ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Second Primary Malignancies

Background. New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We also estimated the proportion of men with CRPC with bone metastases and overall survival. Methods. We conducted a retrospective cohort study of United States (US) men aged ≥ 65 years with CRPC. Cohort entry was from January 1, 2000, to December 31, 2011, with follow-up through December 31, 2013. Castration resistance was defined by treatment with second-line systemic therapy (after surgical or medical castration). SPM were diagnoses of primary cancers (other than prostate) in SEER or Medicare data. Results. Altogether 2,234 patients met eligibility criteria. Most (1,887; 84.5%) had evidence of bone metastases in Medicare claims. SPM occurred in 172 patients (incidence rate 5.9 per 100 person-years; 95% confidence interval [CI], 5.0-6.8; standardized incidence ratio = 3.1, 95% CI, 2.8-3.6, based on SEER incidence rate of all malignancies except prostate cancer among men aged ≥ 65 years). The most common SPM were lung/bronchus (n = 29, 16.9%), urinary bladder (n = 22, 12.8%), and colon/rectum (n = 21, 12.2%). Median survival was 1.2 years (95% CI, 1.1-1.3); 5-year survival was 9% (95% CI, 7-11%). Conclusions. This study provides the first estimate of SPM risk in older men with CRPC in the US. The incidence rate is approximately threefold higher than the population-based cancer incidence among men without prostate cancer.

scholarly journals Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0175217 ◽  
Author(s):  
Chao-Yueh Fan ◽  
Wen-Yen Huang ◽  
Chun-Shu Lin ◽  
Yu-Fu Su ◽  
Cheng-Hsiang Lo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancies

scholarly journals Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
Manette A. W. Dinnessen ◽  
Otto Visser ◽  
Sanne H. Tonino ◽  
Eduardus F. M. Posthuma ◽  
Nicole M. A. Blijlevens ◽  
...  
Keyword(s):  
The Netherlands ◽  
Follicular Lymphoma ◽  
Population Based ◽  
Second Primary ◽  
Population Based Study ◽  
Second Primary Malignancies

scholarly journals Second Primary Malignancies in Patients with Colorectal Cancer: A Population‐Based Analysis

2020 ◽  
Vol 25 (4) ◽  
Author(s):  
Huixun Jia ◽  
Qingguo Li ◽  
Jing Yuan ◽  
Xiaodong Sun ◽  
Zhenyu Wu
Keyword(s):  
Colorectal Cancer ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancies

scholarly journals Mortality of lung cancer as a second primary malignancy: A population‐based cohort study

2019 ◽  
Vol 8 (6) ◽  
pp. 3269-3277
Author(s):  
Lei Deng ◽  
Hrönn Harðardottír ◽  
Huan Song ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy
Sign in / Sign up

Export Citation Format

Share Document